Study hypothesis

Ethics approval

Ethics approval received from the Research Ethics Board of the Ottawa Hospital (Canada) on the 10th May 2007 (for English-speaking patients) and 31st May 2007 (for French-speaking patients) (ref: 2006603-01H).

The hormonal and ultrasound assessments will be done at 0, 3, 6, 9 and 12 months, in both study arms, post cessation.

Overall trial start date

01/01/2007

Overall trial end date

31/12/2008

Reason abandoned

Eligibility

Participant inclusion criteria

Women who are:1. Between ages 18 to 382. Who will be undergoing gonadotoxic (sterilising) curative/adjuvant chemotherapy for early stage disease; and 3. Have provided informed consent

All subjects will be enrolled from the Ottawa Hospital Regional Cancer Institute (OHRCC) and the Cancer Center of South Eastern Ontario at Kingston General Hospital (CCSEO).

Participant type

Patient

Age group

Adult

Gender

Female

Target number of participants

30

Participant exclusion criteria

Women who:1. Have advanced stage disease and/or whose median survival is expected to be less than 6 months 2. Have cancer of the ovaries, uterus, or fallopian tubes 3. Have clinical or biochemical evidence of diminished ovarian reserve (recent shortening of cycles less than 24 days between menses, age greater than 38, elevated serum follicular stimulating hormone (FSH) greater than 15 IU/L, or low antral follicle count (AFC - number of follicles less than 10 mm on day 2 or 3 of natural menses) on baseline pelvic ultrasound (less than 5) or elevated day 2 or 3 estradiol (greater than 280 pmol/ml)4. Have previously received chemotherapy or abdominal/pelvic radiation or have planned to receive abdomino/pelvic radiation5. Are pregnant6. Have contraindications to intramuscular injections; or 7. Have a history of fractures secondary to/or documented osteoporosis